<VariationArchive VariationID="845547" VariationName="NM_000203.5(IDUA):c.1395dup (p.Gly466fs)" VariationType="Duplication" Accession="VCV000845547" Version="7" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-07-15" DateCreated="2020-04-15" MostRecentSubmission="2024-04-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="828638" VariationID="845547">
      <GeneList>
        <Gene Symbol="IDUA" FullName="alpha-L-iduronidase" GeneID="3425" HGNC_ID="HGNC:5391" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>4p16.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="986997" stop="1008351" display_start="986997" display_stop="1008351" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="980784" stop="998316" display_start="980784" display_stop="998316" Strand="+" />
          </Location>
          <OMIM>252800</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000203.5(IDUA):c.1395dup (p.Gly466fs)</Name>
      <CanonicalSPDI>NC_000004.12:1002931:CCCCCC:CCCCCCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>4p16.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="1002931" stop="1002932" display_start="1002931" display_stop="1002932" variantLength="1" positionVCF="1002931" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="996719" stop="996720" display_start="996719" display_stop="996720" variantLength="1" positionVCF="996719" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <ProteinChange>G334fs</ProteinChange>
      <ProteinChange>G466fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.11" sequenceAccession="NC_000004" sequenceVersion="11" change="g.996725dup" Assembly="GRCh37">
            <Expression>NC_000004.11:g.996725dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.12" sequenceAccession="NC_000004" sequenceVersion="12" change="g.1002937dup" Assembly="GRCh38">
            <Expression>NC_000004.12:g.1002937dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008103.1" sequenceAccession="NG_008103" sequenceVersion="1" change="g.20941dup">
            <Expression>NG_008103.1:g.20941dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000203.5" sequenceAccession="NM_000203" sequenceVersion="5" change="c.1395dup" MANESelect="true">
            <Expression>NM_000203.5:c.1395dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000194.2" sequenceAccession="NP_000194" sequenceVersion="2" change="p.Gly466fs">
            <Expression>NP_000194.2:p.Gly466fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001363576.1" sequenceAccession="NM_001363576" sequenceVersion="1" change="c.999dup">
            <Expression>NM_001363576.1:c.999dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001350505.1" sequenceAccession="NP_001350505" sequenceVersion="1" change="p.Gly334fs">
            <Expression>NP_001350505.1:p.Gly334fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_110313.1" sequenceAccession="NR_110313" sequenceVersion="1" change="n.1483dup">
            <Expression>NR_110313.1:n.1483dup</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1277" sequenceAccession="LRG_1277">
            <Expression>LRG_1277:g.20941dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1277t1" sequenceAccession="LRG_1277t1">
            <Expression>LRG_1277t1:c.1395dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1277p1" sequenceAccession="LRG_1277p1" change="p.Gly466fs">
            <Expression>LRG_1277p1:p.Gly466fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1386109118" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000203.5(IDUA):c.1395dup (p.Gly466fs) AND Mucopolysaccharidosis type 1" Accession="RCV001048633" Version="5">
        <ClassifiedConditionList TraitSetID="22506">
          <ClassifiedCondition DB="MedGen" ID="C0023786">Mucopolysaccharidosis type 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-12-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000203.5(IDUA):c.1395dup (p.Gly466fs) AND Hurler syndrome" Accession="RCV003992434" Version="1">
        <ClassifiedConditionList TraitSetID="3230">
          <ClassifiedCondition DB="MedGen" ID="C0086795">Hurler syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-04-04" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-04-04" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2020-04-15" MostRecentSubmission="2024-04-15">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11735025</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21480867</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="22506" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="7856" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Mucopolysaccharidosis type I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Attenuated MPS I (subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Severe MPS I (subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hurler syndrome (former subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hurler-Scheie syndrome (former subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Scheie syndrome (former subtype; formerly known as Mucopoly-saccharidosis type V)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha-L-Iduronidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">IDUA deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MPS I</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Mucopolysaccharidosis type 1</ElementValue>
                <XRef ID="MONDO:0001586" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MPS1</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10335" />
                <XRef ID="10335" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="579" DB="Orphanet" />
              <XRef ID="C0023786" DB="MedGen" />
              <XRef ID="MONDO:0001586" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="3230" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5271" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hurler syndrome</ElementValue>
                <XRef ID="MONDO:0011758" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MUCOPOLYSACCHARIDOSIS TYPE IH</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Gargoylism, Hurler Syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">MPS1-H</ElementValue>
                <XRef Type="MIM" ID="607014" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">MPS I H</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Mucopolysaccharidosis type I (MPS I) is a progressive multisystem disorder with features ranging over a continuum of severity. While affected individuals have traditionally been classified as having one of three MPS I syndromes (Hurler syndrome, Hurler-Scheie syndrome, or Scheie syndrome), no easily measurable biochemical differences have been identified and the clinical findings overlap. Affected individuals are best described as having either a phenotype consistent with either severe (Hurler syndrome) or attenuated MPS I, a distinction that influences therapeutic options. Severe MPS I. Infants appear normal at birth. Typical early manifestations are nonspecific (e.g., umbilical or inguinal hernia, frequent upper respiratory tract infections before age 1 year). Coarsening of the facial features may not become apparent until after age one year. Gibbus deformity of the lower spine is common and often noted within the first year. Progressive skeletal dysplasia (dysostosis multiplex) involving all bones is universal, as is progressive arthropathy involving most joints. By age three years, linear growth decreases. Intellectual disability is progressive and profound but may not be readily apparent in the first year of life. Progressive cardiorespiratory involvement, hearing loss, and corneal clouding are common. Without treatment, death (typically from cardiorespiratory failure) usually occurs within the first ten years of life. Attenuated MPS I. Clinical onset is usually between ages three and ten years. The severity and rate of disease progression range from serious life-threatening complications leading to death in the second to third decade, to a normal life span complicated by significant disability from progressive joint manifestations and cardiorespiratory disease. While some individuals have no neurologic involvement and psychomotor development may be normal in early childhood, learning disabilities and psychiatric manifestations can be present later in life. Hearing loss, cardiac valvular disease, respiratory involvement, and corneal clouding are common.</Attribute>
                <XRef ID="NBK1162" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12559" />
                <XRef ID="12559" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301341</ID>
                <ID Source="BookShelf">NBK1162</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, alpha-L-iduronidase deficiency with or without glycosaminoglycan (GAG) accumulation, Mucopolysaccharidosis Type 1 (MPS I), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/MPSI-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, MPS I: Decreased Alpha-L-Iduronidase; Elevated Dermatan and Heparan Sulfates, 2023</CitationText>
              </Citation>
              <XRef ID="93473" DB="Orphanet" />
              <XRef ID="C0086795" DB="MedGen" />
              <XRef ID="MONDO:0011758" DB="MONDO" />
              <XRef Type="MIM" ID="607014" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2378000" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="5950294|MedGen:C0023786" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001212647" DateUpdated="2024-02-20" DateCreated="2020-04-15" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">11735025</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21480867</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Gly466Argfs*43) in the IDUA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in IDUA are known to be pathogenic (PMID: 11735025, 21480867). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with IDUA-related conditions. ClinVar contains an entry for this variant (Variation ID: 845547). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="IDUA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000004.11:g.996719_996720insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0023786" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8992419" SubmissionDate="2024-04-05" DateLastUpdated="2024-04-15" DateCreated="2024-04-15">
        <ClinVarSubmissionID localKey="NM_000203.5:c.1395dup|OMIM:607014" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004809902" DateUpdated="2024-04-15" DateCreated="2024-04-15" Type="SCV" Version="1" SubmitterName="Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center" OrgID="508075" OrganizationCategory="other" OrgAbbreviation="CGM_KFSHRC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-04-04">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000203.5:c.1395dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="607014" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14359275</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2378000" TraitType="Disease" MappingType="XRef" MappingValue="C0023786" MappingRef="MedGen">
        <MedGen CUI="C0023786" Name="Mucopolysaccharidosis type 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8992419" TraitType="Disease" MappingType="XRef" MappingValue="607014" MappingRef="OMIM">
        <MedGen CUI="C0086795" Name="Hurler syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

